/
/
Clinical Trial: Pomalidomide, Elotuzumab and Low-dose Dexamethasone for Relapsed Myeloma
Clinical Trial: Pomalidomide, Elotuzumab and Low-dose Dexamethasone for Relapsed Myeloma image
Clinical Trial: Pomalidomide, Elotuzumab and Low-dose Dexamethasone for Relapsed Myeloma
Posted Nov 02, 2016

Elotuzumab is an immunotherapy called a monoclonal antibody. It was approved for use in November of 2015 to be used with lenalidomide and dexamethasone. Researchers are now testing elotuzumab with another drug in the same class of immunomodulator drugs called pomalidomide to see if it has similar impact in the treatment on myeloma. In this study, researchers are comparing pomalidomide and low-dose dexamethasone vs. pomalidomide, low-dose dex and elotuzumab. The trial aims to include over 120 patients and is open in 11 locations in the US. To learn more about this clinical trial, click here: Elotuzumab, Pom, Dex for Relapsed/Refractory Myeloma

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811